A phase I trial of CK-0801 in patients with autoimmune diseases and inflammatory disorders

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Jun 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CK 0801 (Primary)
Indications Aplastic anaemia; Autoimmune disorders; Bone marrow disorders; Inflammation; Myelodysplastic syndromes; Myelofibrosis
Focus Adverse reactions
Sponsors Cellenkos

10 Jun 2018 According to a Cellenkos Inc. media release,the United States Food and Drug Administration has cleared the Investigational New Drug (IND) application which allows for Cellenkosto proceed with a phase I clinical trial of CK0801
10 Jun 2018 According to a Cellenkos Inc. media release, the company plans to initiate this trial in in the third quarter of 2018 at The University of Texas MD Anderson Cancer Center, Houston, Texas
07 Feb 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com